OpenJ-Gate
   7383 Open Access Journals
      (4337 Peer-Reviewed)
OpenJ-Gate

Quick Search |  Advanced Search |  Browse Journals: by Title |  by Publisher |  by Subject 
Cancer Journal for Clinicians  [Peer Reviewed]
(Published By: American Cancer Society)
Table Of Contents
[Archives]
Currently Viewing: Vol. 60, No. 4,   Aug,      2010       
  1Angiogenesis Inhibitors: Current Strategies and Future Prospects
  Reprint Author E-mail : wdfigg@helix.nih.gov
   Author(s):Kristina M. Cook ; William D. Figg
  Author Address : Molecular Pharmacology Section, Medical Oncology Branch and Af.liates, National Cancer Institute, National Institutes of Health, 10 Center Drive, 9000 Rockville Pike, Building 10, Room 5A01, Bethesda, MD 20892
  Keyword(s) :Angiogenesis Inhibitors;Drug Therapy;Tumor Growth;Food and Drug Administration;Signaling Molecules;Vascular Endothelial Growth Factor;Platelet-Derived Growth Factor;Fibroblast Growth Factors
  Abstract:

Angiogenesis has become an attractive target for drug therapy because of its key role in tumor growth. An extensive array of compounds is currently in preclinical development, with many now entering the clinic and/or achieving approval from the US Food and Drug Administration. Several regulatory and signaling molecules governing angiogenesis are of interest, including growth factors (eg, vascular endothelial growth factor, platelet-derived growth factor, fibroblast growth factor, and epidermal growth factor), receptor tyrosine kinases, and transcription factors such as hypoxia inducible factor, as well as molecules involved in mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) signaling. Pharmacologic agents have been identified that target these pathways, yet for some agents (notably thalidomide), an understanding of the specific mechanisms of antitumor action has proved elusive. The following review describes key molecular mechanisms and novel therapies that are on the horizon for antiangiogenic tumor therapy. CA Cancer J Clin 2010. © 2010 American Cancer Society, Inc.

    
   
  2Bladder Cancer in 2010: How Far have we Come?
  Reprint Author E-mail : jacobsbl@upmc.edu
   Author(s):Bruce L. Jacobs; Cheryl T. Lee; James E. Montie
  Author Address : Department of Urology, University of Pittsburgh School of Medicine, 3471 Fifth Avenue, Suite 700, Pittsburgh, PA 15213-3232
  Keyword(s) :Bladder Cancer;United States;Neoadjuvant Chemotherapy;American Cancer Society;Cystectomy;Surveillance
  Abstract:

Bladder cancer is the fourth most common cancer and ranks eighth as a cause of death from cancer among men in the United States. Although guidelines assist in treatment, the art of managing bladder cancer, such as the decision to use neoadjuvant chemotherapy and the timing of cystectomy, is still variable. Bladder cancer has a propensity to recur, and with recurrence, a significant number of cases progress, which makes the early detection of high-risk patients imperative. Advances in detection, surveillance, and treatment of bladder cancer are reviewed in this article. CA Cancer J Clin 2010. © 2010 American Cancer Society, Inc.

    
   
  3Diabetes and Cancer: A Consensus Report
  Reprint Author E-mail : egiovann@hsph.harvard.edu
   Author(s):Edward Giovannucci; David M. Harlan; Michael C. Archer; Richard M. Bergenstal; Susan M. Gapstur; Laurel A. Habel; Michael Pollak; Judith G. Regensteiner; Douglas Yee
  Author Address : Departments of Nutrition and Epidemiology, Harvard School of Public Health, 655 Huntington Avenue, Boston, MA, 02115
  Keyword(s) :American Cancer Society;Epidemiologic Evidences;Diabetes Risk Factors;Consensus Statement;Biologic Links;Cancer Prognosis
  Abstract:

Epidemiologic evidence suggests that cancer incidence is associated with diabetes as well as certain diabetes risk factors and treatments. This consensus statement of experts assembled jointly by the American Diabetes Association and the American Cancer Society reviews the state of science concerning 1) the association between diabetes and cancer incidence or prognosis; 2) risk factors common to both diabetes and cancer; 3) possible biologic links between diabetes and cancer risk; and 4) whether diabetes treatments influence the risk of cancer or cancer prognosis. In addition, key unanswered questions for future research are posed. CA Cancer J Clin 2010. © 2010 American Cancer Society, Inc.

    
   
AdverTisements
AdverTisements

 
  What's New | Browser Compatibility | About Open J-Gate | Feedback | Contact                     
                                           ©Informatics India Ltd 2010